A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
Th1187 details |
| Primary information | |
|---|---|
| ID | 1772 |
| ThPP ID | Th1187 |
| Therapeutic Peptide/Protein Name | Human Rho(D) immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIb |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 24 - 30.9 days |
| Description | Human Rho(D) immune globulin is a medicine given by intramuscular injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Human Rho(D) immune globulin is produced by an ion-exchange chromatography isolation procedure, using pooled plasma obtained by plasmapheresis of immunized Rh0(D)-negative US donors. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | It acts by suppressing the immune response of Rh-negative individuals to Rh-positive red blood cells. The mechanism of action is unknown. RhoGAM, MICRhoGAM and other Rho(D) Immune Globulin (Human) products are not effective in altering the course or consequences of Rh immunization once it has occurred. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | 7.3 - 8.6 L |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Hyp Rho D Inj 16.5% |
| Company | Cutter Med & Biol, Division Of Miles Canada Ltd. |
| Brand Discription | NA |
| Prescribed for | NA |
| Chemical Name | NA |
| Formulation | 16.50% |
| Physcial Appearance | liquid |
| Route of Administration | Intramuscular |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link | http://www.rxlist.com/rhogam-ultra-filtered-plus-drug/clinical-pharmacology.htm |
| PubMed ID | 2824867 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1773 |
| ThPP ID | Th1187 |
| Therapeutic Peptide/Protein Name | Human Rho(D) immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIb |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 24 - 30.9 days |
| Description | Human Rho(D) immune globulin is a medicine given by intramuscular injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Human Rho(D) immune globulin is produced by an ion-exchange chromatography isolation procedure, using pooled plasma obtained by plasmapheresis of immunized Rh0(D)-negative US donors. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | It acts by suppressing the immune response of Rh-negative individuals to Rh-positive red blood cells. The mechanism of action is unknown. RhoGAM, MICRhoGAM and other Rho(D) Immune Globulin (Human) products are not effective in altering the course or consequences of Rh immunization once it has occurred. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | 7.3 - 8.6 L |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Hyperrho S/d Full Dose |
| Company | GRIFOLS USA, LLC |
| Brand Discription | NA |
| Prescribed for | NA |
| Chemical Name | NA |
| Formulation | 1500 [iU]/1 |
| Physcial Appearance | Soution |
| Route of Administration | Intramuscular |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link | http://www.rxlist.com/rhogam-ultra-filtered-plus-drug/clinical-pharmacology.htm |
| PubMed ID | 2824867 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1774 |
| ThPP ID | Th1187 |
| Therapeutic Peptide/Protein Name | Human Rho(D) immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIb |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 24 - 30.9 days |
| Description | Human Rho(D) immune globulin is a medicine given by intramuscular injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Human Rho(D) immune globulin is produced by an ion-exchange chromatography isolation procedure, using pooled plasma obtained by plasmapheresis of immunized Rh0(D)-negative US donors. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | It acts by suppressing the immune response of Rh-negative individuals to Rh-positive red blood cells. The mechanism of action is unknown. RhoGAM, MICRhoGAM and other Rho(D) Immune Globulin (Human) products are not effective in altering the course or consequences of Rh immunization once it has occurred. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | 7.3 - 8.6 L |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Hyperrho S/d Mini-dose |
| Company | GRIFOLS USA, LLC |
| Brand Discription | NA |
| Prescribed for | NA |
| Chemical Name | NA |
| Formulation | 250 [iU]/1 |
| Physcial Appearance | Solution |
| Route of Administration | Intramuscular |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link | http://www.rxlist.com/rhogam-ultra-filtered-plus-drug/clinical-pharmacology.htm |
| PubMed ID | 2824867 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1775 |
| ThPP ID | Th1187 |
| Therapeutic Peptide/Protein Name | Human Rho(D) immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIb |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 24 - 30.9 days |
| Description | Human Rho(D) immune globulin is a medicine given by intramuscular injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Human Rho(D) immune globulin is produced by an ion-exchange chromatography isolation procedure, using pooled plasma obtained by plasmapheresis of immunized Rh0(D)-negative US donors. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | It acts by suppressing the immune response of Rh-negative individuals to Rh-positive red blood cells. The mechanism of action is unknown. RhoGAM, MICRhoGAM and other Rho(D) Immune Globulin (Human) products are not effective in altering the course or consequences of Rh immunization once it has occurred. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | 7.3 - 8.6 L |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Micrhogam Ultra-filtered Plus |
| Company | Kedrion Melville, Inc. |
| Brand Discription | NA |
| Prescribed for | NA |
| Chemical Name | NA |
| Formulation | 50 ug/1 |
| Physcial Appearance | injection, solution |
| Route of Administration | Intramuscular |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link | http://www.rxlist.com/rhogam-ultra-filtered-plus-drug/clinical-pharmacology.htm |
| PubMed ID | 2824867 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1776 |
| ThPP ID | Th1187 |
| Therapeutic Peptide/Protein Name | Human Rho(D) immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIb |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 24 - 30.9 days |
| Description | Human Rho(D) immune globulin is a medicine given by intramuscular injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Human Rho(D) immune globulin is produced by an ion-exchange chromatography isolation procedure, using pooled plasma obtained by plasmapheresis of immunized Rh0(D)-negative US donors. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | It acts by suppressing the immune response of Rh-negative individuals to Rh-positive red blood cells. The mechanism of action is unknown. RhoGAM, MICRhoGAM and other Rho(D) Immune Globulin (Human) products are not effective in altering the course or consequences of Rh immunization once it has occurred. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | 7.3 - 8.6 L |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Rhogam Ultra-filtered Plus |
| Company | Kedrion Melville, Inc. |
| Brand Discription | NA |
| Prescribed for | NA |
| Chemical Name | NA |
| Formulation | 300 ug/1 |
| Physcial Appearance | injection, solution |
| Route of Administration | Intramuscular |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link | http://www.rxlist.com/rhogam-ultra-filtered-plus-drug/clinical-pharmacology.htm |
| PubMed ID | 2824867 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1777 |
| ThPP ID | Th1187 |
| Therapeutic Peptide/Protein Name | Human Rho(D) immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIb |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 24 - 30.9 days |
| Description | Human Rho(D) immune globulin is a medicine given by intramuscular injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Human Rho(D) immune globulin is produced by an ion-exchange chromatography isolation procedure, using pooled plasma obtained by plasmapheresis of immunized Rh0(D)-negative US donors. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | It acts by suppressing the immune response of Rh-negative individuals to Rh-positive red blood cells. The mechanism of action is unknown. RhoGAM, MICRhoGAM and other Rho(D) Immune Globulin (Human) products are not effective in altering the course or consequences of Rh immunization once it has occurred. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | 7.3 - 8.6 L |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Rhophylac |
| Company | Csl Behring Ag |
| Brand Discription | NA |
| Prescribed for | NA |
| Chemical Name | NA |
| Formulation | 1500 [iU]/2mL |
| Physcial Appearance | solution |
| Route of Administration | intramuscular; intravenous |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link | http://www.rxlist.com/rhogam-ultra-filtered-plus-drug/clinical-pharmacology.htm |
| PubMed ID | 2824867 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1778 |
| ThPP ID | Th1187 |
| Therapeutic Peptide/Protein Name | Human Rho(D) immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIb |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 24 - 30.9 days |
| Description | Human Rho(D) immune globulin is a medicine given by intramuscular injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Human Rho(D) immune globulin is produced by an ion-exchange chromatography isolation procedure, using pooled plasma obtained by plasmapheresis of immunized Rh0(D)-negative US donors. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | It acts by suppressing the immune response of Rh-negative individuals to Rh-positive red blood cells. The mechanism of action is unknown. RhoGAM, MICRhoGAM and other Rho(D) Immune Globulin (Human) products are not effective in altering the course or consequences of Rh immunization once it has occurred. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | 7.3 - 8.6 L |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Winrho Sdf |
| Company | Aptevo Biotherapeutics Llc |
| Brand Discription | NA |
| Prescribed for | NA |
| Chemical Name | NA |
| Formulation | 5000 unit; 1500 unit; 600 unit |
| Physcial Appearance | kit |
| Route of Administration | intramuscular; intravenous |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link | http://www.rxlist.com/rhogam-ultra-filtered-plus-drug/clinical-pharmacology.htm |
| PubMed ID | 2824867 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1779 |
| ThPP ID | Th1187 |
| Therapeutic Peptide/Protein Name | Human Rho(D) immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIb |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 24 - 30.9 days |
| Description | Human Rho(D) immune globulin is a medicine given by intramuscular injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Human Rho(D) immune globulin is produced by an ion-exchange chromatography isolation procedure, using pooled plasma obtained by plasmapheresis of immunized Rh0(D)-negative US donors. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | It acts by suppressing the immune response of Rh-negative individuals to Rh-positive red blood cells. The mechanism of action is unknown. RhoGAM, MICRhoGAM and other Rho(D) Immune Globulin (Human) products are not effective in altering the course or consequences of Rh immunization once it has occurred. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Winrho Sdf (liquid Formulation) |
| Company | Aptevo Biotherapeutics Llc |
| Brand Discription | NA |
| Prescribed for | NA |
| Chemical Name | NA |
| Formulation | 15000 unit |
| Physcial Appearance | liquid |
| Route of Administration | intramuscular; intravenous |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link | http://www.rxlist.com/rhogam-ultra-filtered-plus-drug/clinical-pharmacology.htm |
| PubMed ID | 2824867 |
| 3-D Structure | N.A. |